Although danuglipron is no longer in the pipeline, Pfizer remains committed to obesity drug development
Compounded medications are not FDA-approved and do not undergo FDA review for safety, effectiveness, or manufacturing quality
Make it a habit
Semaglutide has approvals for reducing cardiovascular risks in patients with heart disease, protecting kidney function in those with chronic kidney disease, and treating metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis
Sources Glucagon-Like Peptide-1 Receptor Agonists, PubMed [accessed 16 October 2024] Ozempic 0.5 mg solution for injection in pre-filled pen SmPC, emc [accessed 16 October 2024] Saxenda 6 mg/mL solution for injection in pre-filled pen SmPC, emc [accessed 16 October 2024] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, NEJM [accessed 16 October 2024] Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials, PubMed [accessed 16 October 2024] Semaglutide 24 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial, The Lancet [accessed 16 October 2024] Wegovy 0.25 mg, FlexTouch solution for injection in pre-filled pen SmPC, emc [accessed 16 October 2024] Once-Weekly Semaglutide in Adults with Overweight or Obesity, NEJM [accessed 16 October 2024] Patient Reviews Related Weight Loss Treatments Further Reading on Weight Loss Do Appetite Suppressants Work
It means being intentional about portions and choices
